Lung: Metastatic squamous NSCLC - chemo-immunotherapy
Free question published 18 November 2026
A 66-year-old former smoker is diagnosed with metastatic squamous-cell carcinoma of the lung. PD-L1 tumour proportion score is 5%, and squamous histology makes pemetrexed unsuitable. He has WHO performance status 1. Which first-line regimen is most appropriate?
- APembrolizumab plus carboplatin and pemetrexed
- BOsimertinib
- CCarboplatin and paclitaxel alone
- DSingle-agent pembrolizumab
- EPembrolizumab plus carboplatin and paclitaxel (or nab-paclitaxel)
Why E is correct
In previously untreated metastatic squamous NSCLC, adding pembrolizumab to carboplatin and paclitaxel or nab-paclitaxel improves overall survival (HR 0.64 in the primary analysis). Pemetrexed is not used in squamous histology, so the taxane-based chemo-immunotherapy backbone is the correct choice.
And why the others are not
- APemetrexed is contraindicated in squamous histology, so a pemetrexed-containing regimen is inappropriate.
- BOsimertinib targets EGFR mutations and has no role in driver-negative squamous NSCLC.
- CChemotherapy alone is inferior to adding pembrolizumab in this setting.
- DSingle-agent pembrolizumab applies to high PD-L1 expression; at TPS 5% the chemo-immunotherapy combination is preferred.
Source KEYNOTE-407 - Pembrolizumab plus carboplatin-taxane in metastatic squamous NSCLC — Novello S, Kowalski DM, Luft A, et al. Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. J Clin Oncol. 2023;41(11):1999-2006. (Primary: Paz-Ares L et al, N Engl J Med 2018;379:2040-2051).
More free respiratory questions
- Lung: Metastatic non-squamous NSCLC - chemo-immunotherapy · 07 November 2026
- Lung: First-line ALK-positive NSCLC · 27 October 2026
- Lung: ADAURA - disease-free survival magnitude · 16 October 2026
Sitting in February? Follow the twenty-week plan.
2,500+ cited questions like this one are waiting in the vault.
See plans and pricing